Related Experiment Video
Updated: May 5, 2026

Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction
Published on: October 14, 2016
Cardiac Amyloidosis Versus Other Restrictive Cardiomyopathies: A Retrospective Analysis of Cardiovascular Outcomes
Andrew Sagalov1, Waqas Ullah2, Yevgeniy Brailovsky3
1Department of Internal Medicine, SIU School of Medicine, Springfield, IL, USA.
Insights
Cardiac amyloidosis increases stroke and ventricular tachycardia risks compared to other restrictive cardiomyopathies. In-hospital mortality and most arrhythmias were similar, but further analysis of amyloidosis subtypes is needed.
Area of Science:
- Cardiology
- Cardiovascular Medicine
- Electrophysiology
Background:
- Cardiac amyloidosis (CA) and other restrictive cardiomyopathies (RCM) have distinct cardiovascular risk profiles.
- Increased screening has led to more CA diagnoses, necessitating analysis of its outcomes.
- Previous literature has not well-characterized the arrhythmic burden and cardiovascular risks of CA versus other RCMs.
Purpose of the Study:
- To compare the cardiovascular risks and arrhythmic burden of cardiac amyloidosis with other types of restrictive cardiomyopathies.
- To analyze outcomes including stroke, ventricular tachycardia, atrial fibrillation, and in-hospital mortality.
Main Methods:
- A retrospective analysis of the National Inpatient Sample (NIS) database from 2016-2019.
- Inclusion of adult patients diagnosed with cardiac amyloidosis or other RCMs (e.g., hemochromatosis, cardiac sarcoid).
- Discharge-weighted analysis using survey regressions to account for sample characteristics and weights.
Main Results:
- Cardiac amyloidosis (N=8365) showed a significantly increased risk of stroke (OR=3.91) and ventricular tachycardia (OR=1.98) compared to other RCM (N=4980).
- CA had a decreased risk of atrial fibrillation (OR=0.56).
- In-hospital mortality (P=.72) and risks of heart block and supraventricular arrhythmias were similar between groups.
Conclusions:
- Cardiac amyloidosis is associated with higher risks of stroke and ventricular tachycardia than other RCMs.
- In-hospital mortality and most arrhythmias did not significantly differ between CA and other RCMs.
- Subgroup analysis of light chain (AL) and transthyretin (ATTR) amyloidosis is recommended to further define CA cardiovascular risks.
Background:
The arrhythmic burden and cardiovascular risks of cardiac amyloidosis compared with other types of restrictive cardiomyopathies (RCM), such as hemochromatosis and cardiac sarcoid, have not been well characterized in the literature. An increase in emphasis on screening has resulted in more diagnoses of cardiac amyloidosis and a larger data pool to analyze the cardiovascular outcomes of this cardiomyopathy.
Methods And Results:
We queried the National Inpatient Sample (NIS) database to identify all adult patients diagnosed with cardiac amyloidosis or other RCM between the years 2016 and 2019. Discharge-weighted analysis using survey regressions accounts for discharge weights and characteristics found to be significantly different between groups. A total sample size of 13 345 patients was obtained, including cardiac amyloidosis (N = 8365; 62.7%) and other RCM (N = 4980; 37.3%). Cardiac amyloidosis was associated with a significantly increased risk of stroke (Odds ratio = 3.91: 95% confidence interval = [2.15, 7.11], P < .001) and ventricular tachycardia (1.98 [1.35-2.91], P < .001). Cardiac amyloidosis had a decreased risk of atrial fibrillation (0.56 [0.47-0.68], P < .001). Significant differences in risk were not observed among the different types of heart block and supraventricular arrhythmias. In-hospital mortality was similar between the 2 groups (P = .72).
Conclusions:
Cardiac amyloidosis was associated with an increased risk of stroke and ventricular tachycardia compared to other types of RCM. Significant differences in in-hospital mortality, bundle branch blocks, and supraventricular arrhythmias were not appreciated. A subgroup analysis comparing light chain (AL) and wild-type transthyretin (ATTR) amyloidosis outcomes would further delineate the cardiovascular risks of cardiac amyloidosis.
More Related Videos
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
08:31Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
Published on: July 26, 2018
Related Concept Videos
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care